Follicular lymphoma: 2014 update on diagnosis and management - Wikidata - awgldk - TriplyDB

Follicular lymphoma: 2014 update on diagnosis and management

Follicular lymphoma: 2014 update on diagnosis and management

http://www.wikidata.org/entity/Q27021850

about

Allogeneic Hematopoietic Cell Transplantation as Curative Therapy for Patients with Non-Hodgkin Lymphoma: Increasingly Successful Application to Older Patients Limited Stage Follicular Lymphoma: Current Role of Radiation Therapy An open-label expanded-access trial of bendamustine in patients with rituximab-refractory indolent non-Hodgkin lymphoma or previously untreated chronic lymphocytic leukemia: BEND-ACT Autologous hematopoietic stem cell transplantation for relapsed follicular lymphoma: safety profile and clinical outcome in a single-center experience.A comprehensive evaluation of the role of genetic variation in follicular lymphoma survival.Proteomics Based Identification of Proteins with Deregulated Expression in B Cell Lymphomas.Coexistence of follicular lymphoma and an unclassifiable myeloproliferative neoplasm in a treatment-naïve patient: A case report Lymphadenopathy: Differentiation between Tuberculosis and Other Non-Tuberculosis Causes like Follicular Lymphoma.Targeting B-cell neoplasia with T-cell receptors recognizing a CD20-derived peptide on patient-specific HLA FBXO10 deficiency and BTK activation upregulate BCL2 expression in mantle cell lymphoma.Tumor suppressors in follicular lymphoma.The preclinical discovery of rituximab for the treatment of non-Hodgkin's lymphoma.Idelalisib for relapsed/refractory indolent B-cell non-Hodgkin's lymphoma: an overview of pharmacokinetics and clinical trial outcomes.The IL-15-Based ALT-803 Complex Enhances FcγRIIIa-Triggered NK Cell Responses and In Vivo Clearance of B Cell Lymphomas.Diagnostic and predictive biomarkers for lymphoma diagnosis and treatment in the era of precision medicine.Positron emission tomography response and minimal residual disease impact on progression-free survival in patients with follicular lymphoma. A subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi.Integrated immunohistochemical and DNA copy number profiling analysis provides insight into the molecular pathogenesis of canine follicular lymphoma.Parameters for Contrast-Enhanced Ultrasound (CEUS) of Enlarged Superficial Lymph Nodes for the Evaluation of Therapeutic Response in Lymphoma: A Preliminary Study.Sites of extranodal involvement are prognostic in patients with stage 1 follicular lymphoma.Abundant expression of BMI1 in follicular lymphoma is associated with reduced overall survival.Refractoriness to immunochemotherapy in follicular lymphoma: Predictive factors and outcome.The use of anthracycline at first-line compared to alkylating agents or nucleoside analogs improves the outcome of salvage treatments after relapse in follicular lymphoma The REFOLL study by the Fondazione Italiana Linfomi.Critically dysregulated signaling pathways and clinical utility of the pathway biomarkers in lymphoid malignancies.Oncogenic Signaling Pathways and Pathway-Based Therapeutic Biomarkers in Lymphoid Malignancies.Low-grade follicular lymphoma involvement of the bone marrow with a mixed paratrabecular, diffuse, and massive pattern expressing typical mantle cell lymphoma immunophenotype CD23-/FMC7+: a case report

P2860

Q28066710-669161C3-9D22-44EE-AB5B-8362DD38EE3E Q28079742-073840BE-D699-4D46-B684-3BAAA3AF9E0A Q33425372-34222CAB-4951-4A58-8F3B-58766859F7DD Q34459589-5ACDC384-C19C-43FC-BBBE-A18D70A48BF5 Q35311162-9D78FDAE-D073-41E2-8A39-7A10382434CB Q35890616-520E654A-D6F9-4573-85FB-62020089E7A6 Q36524740-72E690A4-1F23-47EF-BC42-E40ECC6A2675 Q36615228-64AC39B2-7FE8-4CE5-95A3-571B8BAF6C73 Q37012701-E1889EC0-34CE-407C-8F5A-9CC0CFE01BA4 Q37404843-0CBD372A-4D05-45EE-9880-3BEF7696E165 Q38266066-8E921931-3860-4746-83D6-5164762312E8 Q38530254-76C8A467-F7CD-4C63-B496-A566BE3B63C9 Q38581826-B4EA545A-F1CE-4495-A7A2-AF60C6114F3D Q38831202-95189D9C-7AB8-4C49-8C79-9D24C382FFF4 Q38882112-E8AE2552-6FC0-4607-AA77-AA1B85DCE5A8 Q42427611-04DB915A-5DC2-4F69-8F09-36C3C4A29F4A Q44863958-D55E3284-ADD1-4F46-956A-547BB0EEF166 Q47130685-D62D8617-B2E7-4057-844D-0FE3E4617791 Q47143348-EF5BBA6A-5226-48FD-81B1-1794326031F2 Q47282473-DD768809-1634-4E47-97A7-C8164558C8C6 Q48280234-F6BFD538-8A9E-488B-8293-B12DB6AF5BF5 Q53010399-AE78F0BF-5EDA-4C0D-84CB-BA74183558C2 Q54982413-676D749A-E3A0-4BF8-B7D3-D657F8A8D6F1 Q55281964-B0DFA34B-79B7-410E-92B5-0B67DD64733B Q57494279-F2DDC859-0367-444B-A105-D65595C4A397

P2860

Follicular lymphoma: 2014 update on diagnosis and management

http://www.wikidata.org/entity/Q27021850

description

2014 nî lūn-bûn

@nan

2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Follicular lymphoma: 2014 update on diagnosis and management

@ast

Follicular lymphoma: 2014 update on diagnosis and management

@en

Follicular lymphoma: 2014 update on diagnosis and management

@nl

type

label

Follicular lymphoma: 2014 update on diagnosis and management

@ast

Follicular lymphoma: 2014 update on diagnosis and management

@en

Follicular lymphoma: 2014 update on diagnosis and management

@nl

prefLabel

Follicular lymphoma: 2014 update on diagnosis and management

@ast

Follicular lymphoma: 2014 update on diagnosis and management

@en

Follicular lymphoma: 2014 update on diagnosis and management

@nl

P1433

Q27021850-D6813450-8D23-4BA0-9BAF-6D21E7B82634

P1476

Q27021850-A15443CE-B40E-490B-828B-8C9FFBB4A922

P2093

Q27021850-46D7882A-4663-4B78-8E90-701B50121647

P2860

Q27021850-014764F6-0B81-44B6-A0F8-BD317BD3B0FE

Q27021850-0798FA57-3170-4A99-824C-00377C4FD960

Q27021850-101700AB-D4C5-4270-B986-9BF3451CC29E

Q27021850-1187DC93-139A-41C9-8A88-C61069C1E6CC

Q27021850-1545306C-9A9F-4901-BF88-5792F9309DC0

Q27021850-16308277-9DD1-480D-93BE-72CA89E8DF8F

Q27021850-1ABEA306-2FD2-44B5-9C2A-CA38108FFDFD

Q27021850-1B944D2A-06C3-4129-AF54-A2E01EDF9FA5

Q27021850-1CB4C001-E8C2-4628-B35A-4FA03C7DF869

Q27021850-201CB095-B766-447C-A496-45ECBAD5CC83

P304

Q27021850-25F20A27-E385-4C0D-8B23-362F4F2899AB

P31

Q27021850-EFB6EDE5-7128-4CA1-9FDD-84A9C4F4AC5B

P3181

Q27021850-49392A6B-2C06-4186-9A3D-86BEF00475D9

P356

Q27021850-DEB4D346-6386-48D1-867F-2F3F79A2A57E

P407

Q27021850-40359516-7BC1-49FE-BD25-BD161FB1D60D

P433

Q27021850-F7B68001-B343-438F-A731-6D557D42872A

P478

Q27021850-A4258E4D-FB8C-4112-BEE7-68D979C07AC2

P577

Q27021850-B1BC9E5A-B4B5-4C5C-A69D-14E616CE66B2

P698

Q27021850-5E6FD103-E165-422F-B146-6A911B34524A

P3181

P356

P1433

American Journal of Hematology

P1476

Follicular lymphoma: 2014 update on diagnosis and management

@en

P2093

Arnold Freedman

http://www.w3.org/2001/XMLSchema#string

P2860

Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98

Placebo-controlled phase III trial of patient-specific immunotherapy with mitumprotimut-T and granulocyte-macrophage colony-stimulating factor after rituximab in patients with follicular lymphoma

(90)Yttrium-ibritumomab-tiuxetan as first-line treatment for follicular lymphoma: 30 months of follow-up data from an international multicenter phase II clinical trial.

Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma.

Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study.

Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma.

Cyclophosphamide, vincristine, and prednisone followed by tositumomab and iodine-131-tositumomab in patients with untreated low-grade follicular lymphoma: eight-year follow-up of a multicenter phase II study.

Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study.

P304

429-36

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3741560

http://www.w3.org/2001/XMLSchema#string

P356

10.1002/AJH.23674

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

89

http://www.w3.org/2001/XMLSchema#string

P577

2014-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24687887

http://www.w3.org/2001/XMLSchema#string